VSV-based Therapeutic Papilloma Vaccine
VSV-based Therapeutic Papilloma Vaccine
批准号:
6761813
负责人:
JANET L BRANDSMA
金额:
$32.74万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-06-17 至 2008-05-31
关键词:
AdenoviridaePapillomavirusVesiculovirusantigen antibody reactionbiotechnologycancer preventioncervix neoplasmschimeric proteinsdisease /disorder modelenzyme linked immunosorbent assayhuman papillomavirusimmunizationimmunoprecipitationimmunotherapylaboratory rabbitmolecular cloningnonhuman therapy evaluationrabbit papillomavirusremission /regressionsexually transmitted diseasestumor antigensubiquitinvaccine developmentvector vaccinevirus envelopewestern blottings
中文摘要
描述(申请人提供):人乳头瘤病毒(HPV)感染宫颈,引发宫颈癌的发展。接种疫苗有可能通过预防原发HPV感染和消除持续性病变来预防宫颈癌。理想的疫苗将诱导治疗性免疫和保护性免疫。开发治疗性疫苗的最佳动物模型是棉尾兔乳头瘤病毒(CRPV)-兔模型。表达外源病毒蛋白的重组活体水泡性口炎病毒(RVSV)已成功地保护动物免受多种人类病毒的攻击。我们最近构建了表达CRPVE6肿瘤抗原的rVSV载体,并将其用于免疫兔已建立的肿瘤(乳头状瘤)进行初步实验。治疗产生了戏剧性的治疗结果,包括一些兔的所有疾病完全和永久地消退,总乳头状瘤负荷为4cm3,而对照组没有消退。这一应用的假设是,可以对rVSV-E6疫苗进行改进,以诱导更快速、更普遍的回归。这是基于观察到原始疫苗表达的E6蛋白水平相对较低,并且由于初次接种诱导了VSV特异性中和抗体,所以用相同的rVSV-E6复种可能无效。通过修饰E6基因编码泛素-E6融合蛋白(UbE6)也可以提高rVSV-E6的效力,基于我们的发现,使用CRPV DNA疫苗,融合基因UbE6明显比未融合E6基因更有效。具体目的是用更大的群体规模和所有适当的对照重复初步实验;确定是否可以使用高水平表达E6或表达UbE6的VSV载体、使用带有来自异源血清型的VSV包膜基因的高效VSV-E6增强载体或使用完全异源的病毒载体(腺病毒)来获得更快、更普遍的肿瘤清除。我们将确定最有效的治疗性疫苗是否也能诱导保护性免疫。这项调查提供的数据可能有助于开发一种高效的HPV疫苗,以保护妇女免受宫颈癌的侵袭。
英文摘要
DESCRIPTION (provided by applicant): Human papillomavirus (HPV) infection of the cervix initiates the development of cervical cancer. Vaccination has the potential to prevent cervical cancer by preventing primary HPV infection and by eliminating persistent lesions. The ideal vaccine would induce therapeutic as well as protective immunity. The best animal model for therapeutic vaccine development is the cottontail rabbit papillomavirus (CRPV)-rabbit model. Live recombinant vesicular stomatitis viruses (rVSV) expressing foreign viral proteins have successfully protected animals against challenges with several human viruses. We recently generated an rVSV vector expressing the CRPV E6 tumor antigen and used it to vaccinate rabbits with well-established tumors (papillomas) in a preliminary experiment. The treatment induced dramatic therapeutic outcomes including the complete and permanent regression of all disease in some rabbits with a total papilloma burden of 4 cm3, as compared to no regression in the controls. The hypothesis of this application is that the rVSV-E6 vaccine can be improved to induce more rapid and more universal regression. It is based on the observation that the original vaccine expressed a relatively low level of E6 protein and that revaccination with the same rVSV-E6 was probably not effective, due to VSV-specific neutralizing antibodies induced by primary vaccination. The efficacy of the rVSV-E6 could also be improved by modifying the E6 gene to encode a ubiquitin-E6 fusion protein (UbE6), based on our findings, using CRPV DNA vaccines, that a UbE6 fused gene was markedly more effective than the unfused E6 gene. The specific aims are to repeat the preliminary experiment with larger group size and all appropriate controls; to determine if more rapid and more universal tumor clearance can be obtained using VSV vectors giving higher-level expression of E6 or expressing UbE6, using an efficient VSV-E6 boosting vector with the VSV envelope gene from a heterologous serotype, or using a completely heterologous viral vector (adenovirus). We will determine if the most effective therapeutic vaccine also induces protective immunity. The data provided by this investigation are likely to aid in the development a highly effective HPV vaccine to protect women against cervical cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Langerhans cell-mediated immune modulation of HPV8 expression and tumorgenesis
-
批准号:7530393
-
项目类别:
-
资助金额:$18.62万
-
财政年份:2008
-
负责人:JANET L BRANDSMA
-
依托单位:
Langerhans cell-mediated immune modulation of HPV8 expression and tumorgenesis
-
批准号:7624197
-
项目类别:
-
资助金额:$22.34万
-
财政年份:2008
-
负责人:JANET L BRANDSMA
-
依托单位:
Papillomavirus E2 as a cervical/anal cancer drug target
-
批准号:6915013
-
项目类别:
-
资助金额:$24.53万
-
财政年份:2004
-
负责人:JANET L BRANDSMA
-
依托单位:
Papillomavirus E2 as a cervical/anal cancer drug target
-
批准号:6844396
-
项目类别:
-
资助金额:$23.39万
-
财政年份:2004
-
负责人:JANET L BRANDSMA
-
依托单位:
VSV-based Therapeutic Papilloma Vaccine
-
批准号:6679199
-
项目类别:
-
资助金额:$31.66万
-
财政年份:2003
-
负责人:JANET L BRANDSMA
-
依托单位:
VSV-based Therapeutic Papilloma Vaccine
-
批准号:7226737
-
项目类别:
-
资助金额:$31.04万
-
财政年份:2003
-
负责人:JANET L BRANDSMA
-
依托单位:
VSV-based Therapeutic Papilloma Vaccine
-
批准号:7060357
-
项目类别:
-
资助金额:$31.97万
-
财政年份:2003
-
负责人:JANET L BRANDSMA
-
依托单位:
VSV-based Therapeutic Papilloma Vaccine
-
批准号:6897543
-
项目类别:
-
资助金额:$32.74万
-
财政年份:2003
-
负责人:JANET L BRANDSMA
-
依托单位:
CTL responses to vaccination in CRPV rabbit model
-
批准号:6445484
-
项目类别:
-
资助金额:$7.23万
-
财政年份:2001
-
负责人:JANET L BRANDSMA
-
依托单位:
GENETIC DETERMINANTS OF HUMAN PAPILLOMAVIRUS PATHOGENICITY
-
批准号:6268828
-
项目类别:
-
资助金额:$16.76万
-
财政年份:1998
-
负责人:JANET L BRANDSMA
-
依托单位:
GENETIC DETERMINANTS OF HUMAN PAPILLOMAVIRUS PATHOGENICITY
-
批准号:6236233
-
项目类别:
-
资助金额:$16.14万
-
财政年份:1997
-
负责人:JANET L BRANDSMA
-
依托单位:
PROTECTIVE AND THERAPEUTIC IMMUNITY TO PAPILLOMATOSIS
-
批准号:3202259
-
项目类别:
-
资助金额:$28.83万
-
财政年份:1992
-
负责人:JANET L BRANDSMA
-
依托单位:
PROTECTIVE AND THERAPEUTIC IMMUNITY TO PAPILLOMATOSIS
-
批准号:2098672
-
项目类别:
-
资助金额:$29.38万
-
财政年份:1992
-
负责人:JANET L BRANDSMA
-
依托单位:
PROTECTIVE AND THERAPEUTIC IMMUNITY TO PAPILLOMATOSIS
-
批准号:2098673
-
项目类别:
-
资助金额:$31.34万
-
财政年份:1992
-
负责人:JANET L BRANDSMA
-
依托单位:
CTL responses to vaccination in CRPV rabbit model
-
批准号:6318510
-
项目类别:
-
资助金额:$7.23万
-
财政年份:1992
-
负责人:JANET L BRANDSMA
-
依托单位:
PROTECTIVE AND THERAPEUTIC IMMUNITY TO PAPILLOMATOSIS
-
批准号:3202258
-
项目类别:
-
资助金额:$28.99万
-
财政年份:1992
-
负责人:JANET L BRANDSMA
-
依托单位:
STUDIES IN VIVO OF PAPILLOMAVIRUS TRANSFORMING GENES
-
批准号:3423644
-
项目类别:
-
资助金额:$8.4万
-
财政年份:1991
-
负责人:JANET L BRANDSMA
-
依托单位:
VIVO OF PAPILLOMAVIRUS TRANSFORMING GENES
-
批准号:3423645
-
项目类别:
-
资助金额:$8.2万
-
财政年份:1991
-
负责人:JANET L BRANDSMA
-
依托单位:
CANCER OF THE HEAD & NECK--EPIDEMIOLOGY AND BIOCHEMISTRY
-
批准号:3177913
-
项目类别:
-
资助金额:$13.04万
-
财政年份:1985
-
负责人:JANET L BRANDSMA
-
依托单位:
CANCER OF THE HEAD & NECK--EPIDEMIOLOGY AND BIOCHEMISTRY
-
批准号:3177914
-
项目类别:
-
资助金额:$14.02万
-
财政年份:1985
-
负责人:JANET L BRANDSMA
-
依托单位:
海外基金